Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
MBOT 
Microbot Medical Inc (MBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: MBOT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.75
1 Year Target Price $8.75
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.88% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 161.85M USD | Price to earnings Ratio - | 1Y Target Price 8.75 |
Price to earnings Ratio - | 1Y Target Price 8.75 | ||
Volume (30-day avg) 1 | Beta 1.17 | 52 Weeks Range 0.93 - 4.67 | Updated Date 12/14/2025 |
52 Weeks Range 0.93 - 4.67 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.17% | Return on Equity (TTM) -31.87% |
Valuation
Trailing PE - | Forward PE 31.75 | Enterprise Value 82591886 | Price to Sales(TTM) - |
Enterprise Value 82591886 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.89 | Shares Outstanding 67158044 | Shares Floating 67158044 |
Shares Outstanding 67158044 | Shares Floating 67158044 | ||
Percent Insiders - | Percent Institutions 13.84 |
About Microbot Medical Inc
Exchange NASDAQ | Headquaters Hingham, MA, United States | ||
IPO Launch date 1992-03-25 | Co-Founder, President, CEO & Chairman Mr. Harel Gadot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 20 | Website https://microbotmedical.com |
Full time employees 20 | Website https://microbotmedical.com | ||
Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.